Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Baxalta
Baxalta
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Finance
Shareholders approve Shire's merger with Baxalta
Will create 'the leading global biotechnology company in rare diseases and other highly specialised conditions', the firms say
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
Latest EU drug approvals span range of health issues
Cancer was again at the forefront of the NMEs reaching the market in 2015, but new drugs also benefited other disease areas. Dr Sarah Houlton looks at the latest therapeutic arrivals
Finance
Shire to buy Baxalta for US$32bn
Creating a global leader in rare diseases
Research & Development
Baxalta agrees $1.6bn cancer deal with Symphogen
Will advance novel therapeutics against six targets
Research & Development
Baxalta opens Global Innovation Centre in Cambridge, MA, US
Will serve as the firm's HQ for R&D, oncology, biosimilars and business development
Finance
Shire makes hostile all-stock US$30bn bid for Baxalta
To create the leading global biotechnology company focused on rare diseases
Research & Development
Baxalta appoints Jacopo Leonardi as EVP and President Immunology
Biopharmaceutical firm specialises in developing and manufacturing plasma-based therapies for rare diseases
Subscribe now